A Scoping Review of the Use of Pioglitazone in the Treatment of Temporo-Mandibular Joint Arthritis
暂无分享,去创建一个
D. Chlubek | M. Sikora | M. Chęciński | M. Kamińska | Zuzanna Nowak | K. Chęcińska | Natalia Turosz | Maciej Sikora | Kamila Chęcińska
[1] P. Cascone,et al. Temporomandibular Joint Surgery: Open Discopexy and "Functional Arthroplasty". , 2022, Atlas of the oral and maxillofacial surgery clinics of North America.
[2] D. Chlubek,et al. Repeated Intra-Articular Administration of Platelet-Rich Plasma (PRP) in Temporomandibular Disorders: A Clinical Case Series , 2022, Journal of clinical medicine.
[3] Hua Chen,et al. Efficacy and Safety of Curcumin and Curcuma longa Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial , 2022, Frontiers in Immunology.
[4] Qilong Wang,et al. The Relationship Between Porphyromonas Gingivalis and Rheumatoid Arthritis: A Meta-Analysis , 2022, Frontiers in cellular and infection microbiology.
[5] D. Chlubek,et al. Treatment of Mandibular Hypomobility by Injections into the Temporomandibular Joints: A Systematic Review of the Substances Used , 2022, Journal of clinical medicine.
[6] Y. Boirie,et al. A Meta-Analysis of the Impact of Nutritional Supplementation on Osteoarthritis Symptoms , 2022, Nutrients.
[7] D. Chlubek,et al. The Administration of Hyaluronic Acid into the Temporomandibular Joints’ Cavities Increases the Mandible’s Mobility: A Systematic Review and Meta-Analysis , 2022, Journal of clinical medicine.
[8] R. Gan,et al. Natural products modulating interleukins and other inflammatory mediators in tumor-bearing animals: A systematic review. , 2022, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[9] L. Argueta-Figueroa,et al. Nonpharmacological Interventions for Pain in Patients with Temporomandibular Joint Disorders: A Systematic Review , 2022, European journal of dentistry.
[10] M. Dougados,et al. 2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis. , 2022, Joint bone spine.
[11] Yue He,et al. Top 100 Cited Articles on Osteoarthritis from 1990 to 2020 , 2021, Rheumatology and immunology research.
[12] A. Caprioglio,et al. Three-dimensional volumetric evaluation of the different mandibular segments using CBCT in patients affected by juvenile idiopathic arthritis: a cross-sectional study , 2021, Progress in Orthodontics.
[13] Aleksandra Nitecka-Buchta,et al. Intramuscular Injections and Dry Needling within Masticatory Muscles in Management of Myofascial Pain. Systematic Review of Clinical Trials , 2021, International journal of environmental research and public health.
[14] Arvind Muthukrishnan,et al. Clinical Practice Guidelines for the Management of Temporomandibular Joint Disorders – A Review , 2021, Journal of Evolution of Medical and Dental Sciences.
[15] J. Espín,et al. Targeting Mammalian 5-Lipoxygenase by Dietary Phenolics as an Anti-Inflammatory Mechanism: A Systematic Review , 2021, International journal of molecular sciences.
[16] B. Sokołowska,et al. Temporomandibular joint disorders in patients with rheumatoid arthritis , 2021, Reumatologia.
[17] E. Pawlowska,et al. Mechanisms of Action and Efficacy of Hyaluronic Acid, Corticosteroids and Platelet-Rich Plasma in the Treatment of Temporomandibular Joint Osteoarthritis—A Systematic Review , 2021, International journal of molecular sciences.
[18] I. Moppett,et al. Preoperative inflammatory mediators and postoperative delirium: systematic review and meta-analysis. , 2021, British journal of anaesthesia.
[19] D. Chlubek,et al. Variants and Modifications of the Retroauricular Approach Using in Temporomandibular Joint Surgery: A Systematic Review , 2021, Journal of clinical medicine.
[20] Y. Chai,et al. Effectiveness of resistance exercises in the treatment of rheumatoid arthritis , 2021, Medicine.
[21] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.
[22] M. Troulis,et al. Is there a difference in treatment effect of different intra-articular drugs for temporomandibular joint osteoarthritis? A systematic review of randomized controlled trials. , 2021, International journal of oral and maxillofacial surgery.
[23] L. Esposito,et al. Safety and Effects of the Rapid Maxillary Expander on Temporomandibular Joint in Subjects Affected by Juvenile Idiopathic Arthritis: A Retrospective Study , 2021, Children.
[24] W. Lu,et al. Role of peroxisome proliferator-activated receptors in osteoarthritis (Review). , 2020, Molecular medicine reports.
[25] S. Hasan,et al. Low-level laser therapy in temporomandibular joint disorders: a systematic review , 2021, Journal of medicine and life.
[26] P. Schrauwen,et al. Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment? , 2020, Molecular metabolism.
[27] Kathryn M. Hurren,et al. Are thiazolidinediones a preferred drug treatment for type 2 diabetes? , 2020, Expert opinion on pharmacotherapy.
[28] M. Ennis,et al. Histamine receptors and COVID-19 , 2020, Inflammation research : official journal of the European Histamine Research Society ... [et al.].
[29] M. Dougados,et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement , 2020, Annals of the Rheumatic Diseases.
[30] M. Borysewicz-Lewicka,et al. Early diagnosis of temporomandibular joint arthritis in children with juvenile idiopathic arthritis. A systematic review. , 2020, European journal of paediatric dentistry.
[31] S. Bonassi,et al. Association of inflammatory mediators with frailty status in older adults: results from a systematic review and meta-analysis , 2020, GeroScience.
[32] F. Bénard,et al. A Systematic Review of Molecular Imaging Agents Targeting Bradykinin B1 and B2 Receptors , 2020, Pharmaceuticals.
[33] Q. Lu,et al. The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review , 2020, Journal of Autoimmunity.
[34] M. Walshe,et al. Modified Diet Use in Adults with Temporomandibular Disorders related to Rheumatoid Arthritis: A Systematic Review , 2020, Mediterranean journal of rheumatology.
[35] D. Chlubek,et al. Short-Term Effects of Intra-Articular Hyaluronic Acid Administration in Patients with Temporomandibular Joint Disorders , 2020, Journal of clinical medicine.
[36] A. Iagnocco,et al. Differential Diagnosis of Inflammatory Arthropathies by Musculoskeletal Ultrasonography: A Systematic Literature Review , 2020, Frontiers in Medicine.
[37] B. Koes,et al. Non-steroidal anti-inflammatory drugs for acute low back pain. , 2020, The Cochrane database of systematic reviews.
[38] M. Wiese,et al. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis , 2020, Expert opinion on investigational drugs.
[39] T. Kawaguchi,et al. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis , 2020, International journal of molecular sciences.
[40] J. Erickson,et al. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1) , 2020, Rheumatology.
[41] J. R. Neto,et al. Pharmacological strategies for insulin sensitivity: thiazolidinediones and metformin. , 2020, Current pharmaceutical design.
[42] H. Lebovitz. Thiazolidinediones: the Forgotten Diabetes Medications , 2019, Current Diabetes Reports.
[43] Xiaobo Zhu,et al. PPARγ preservation via promoter demethylation alleviates osteoarthritis in mice , 2019, Annals of the rheumatic diseases.
[44] W. Ahsan. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective. , 2019, Current pharmaceutical design.
[45] M. Si,et al. PPAR-γ agonist pioglitazone protects against IL-17 induced intervertebral disc inflammation and degeneration via suppression of NF-κB signaling pathway. , 2019, International immunopharmacology.
[46] N. Sheibani,et al. The impact of water molecules on binding affinity of the anti-diabetic thiazolidinediones for catalase: Kinetic and mechanistic approaches. , 2019, Archives of biochemistry and biophysics.
[47] R. Christensen,et al. Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases. , 2018, The Cochrane database of systematic reviews.
[48] J. McGowan,et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation , 2018, Annals of Internal Medicine.
[49] R. Xavier,et al. Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta‐analysis , 2018, Journal of cachexia, sarcopenia and muscle.
[50] G. De Sarro,et al. Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators , 2018, PeerJ.
[51] L. Serra-Majem,et al. Osteoarthritis and the Mediterranean Diet: A Systematic Review , 2018, Nutrients.
[52] Manna Zhang,et al. Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study , 2018, International journal of medical sciences.
[53] N. Horita,et al. Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis: systematic review and meta-analysis , 2018, Rheumatology.
[54] P. Bundhun,et al. Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials , 2017, BMC Pharmacology and Toxicology.
[55] I. Banerjee,et al. Effects of co-treatment with pioglitazone and methotrexate on experimentally induced rheumatoid arthritis in Wistar albino rats , 2017, Indian journal of pharmacology.
[56] A. Sidebottom,et al. Management of the temporomandibular joint in inflammatory arthritis: Involvement of surgical procedures. , 2017, European journal of rheumatology.
[57] Chi Ma,et al. Pioglitazone inhibits advanced glycation end product-induced matrix metalloproteinases and apoptosis by suppressing the activation of MAPK and NF-κB , 2016, Apoptosis.
[58] M. Masiuk,et al. Effect of methylprednisolone, hyaluronic acid and pioglitazone on histological remodeling of temporomandibular joint cartilage in rabbits affected by drug-induced osteoarthritis. , 2016, Postepy higieny i medycyny doswiadczalnej.
[59] Y. Xia,et al. Establishment of a rabbit model to study the influence of advanced glycation end products accumulation on osteoarthritis and the protective effect of pioglitazone. , 2016, Osteoarthritis and cartilage.
[60] M. Erić,et al. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2016): Poster Abstracts , 2016, Osteoporosis International.
[61] S. Gupta,et al. Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study , 2015, Indian journal of endocrinology and metabolism.
[62] I. Dicembrini,et al. Drugs for type 2 diabetes: role in the regulation of bone metabolism. , 2015, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.
[63] K. Tsai,et al. PPARγ is involved in the hyperglycemia‐induced inflammatory responses and collagen degradation in human chondrocytes and diabetic mouse cartilages , 2015, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[64] V. Chapman,et al. Characterisation of Pain Responses in the High Fat Diet/Streptozotocin Model of Diabetes and the Analgesic Effects of Antidiabetic Treatments , 2015, Journal of diabetes research.
[65] Ying Zhang,et al. Pioglitazone Inhibits Advanced Glycation End Product-Induced TNF-E and MMP-13 Expression via the Antagonism of NF-TB Activation in Chondrocytes , 2014, Pharmacology.
[66] M. A. Mohamed,et al. Effect of pentoxifylline and pioglitazone on rheumatoid arthritis induced experimentally in rats , 2014 .
[67] A. Shintani,et al. Reversing Vascular Dysfunction in Rheumatoid Arthritis: Improved Augmentation Index but Not Endothelial Function With Peroxisome Proliferator–Activated Receptor γ Agonist Therapy , 2014, Arthritis & Rheumatology.
[68] D. Jiang,et al. PPAR-γ agonist pioglitazone affects rat gouty arthritis by regulating cytokines. , 2014, Genetics and molecular research : GMR.
[69] K. Al-shamma,et al. Evaluation of the Clinical use of Metformin or Pioglitazone in Combination with Meloxicam in Patients with Knee Osteoarthritis; using Knee Injury and Osteoarthritis outcome Score , 2014 .
[70] R. Brook,et al. The Peroxisome Proliferator Activated Receptor‐γ Pioglitazone Improves Vascular Function and Decreases Disease Activity in Patients With Rheumatoid Arthritis , 2013, Journal of the American Heart Association.
[71] D. Chappard,et al. The peroxisome proliferator-activated receptor γ agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway. , 2013, Arthritis and rheumatism.
[72] A. Consoli,et al. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? , 2013, Diabetes, obesity & metabolism.
[73] S. Suke,et al. Anti-arthritic and anti-inflammatory activity of combined pioglitazone and prednisolone on adjuvant-induced arthritis. , 2013, European journal of pharmacology.
[74] C. Stein,et al. Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial , 2013, Arthritis Research & Therapy.
[75] Thomas M. MacDonald,et al. Pioglitazone and bladder cancer: a propensity score matched cohort study. , 2013, British journal of clinical pharmacology.
[76] David Samson,et al. Chapter 2: Medical Tests Guidance (2) Developing the Topic and Structuring Systematic Reviews of Medical Tests: Utility of PICOTS, Analytic Frameworks, Decision Trees, and Other Frameworks , 2012, Journal of general internal medicine.
[77] A. Ferrara,et al. Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes , 2011, Diabetes Care.
[78] J. Pelletier,et al. Peroxisome proliferator-activated receptor gamma in osteoarthritis , 2011, Modern rheumatology.
[79] V. Boshra,et al. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders Effect of Peroxisome Proliferator-activated Receptor Gamma Agonist (pioglitazone) and Methotrexate on Disease Activity in Rheumatoid Arthritis (experimental and Clinical Study) , 2022 .
[80] Chia-Ron Yang,et al. THIAZOLIDINEDIONES INHIBIT TNF-&agr;-MEDIATED OSTEOCLAST DIFFERENTIATION OF RAW264.7 MACROPHAGES AND MOUSE BONE MARROW CELLS THROUGH DOWNREGULATION OF NFATc1 , 2010, Shock.
[81] S. Mudaliar,et al. Pioglitazone: side effect and safety profile , 2010, Expert opinion on drug safety.
[82] K. Menon,et al. Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro. , 2007, Fertility and sterility.
[83] S. Theocharis,et al. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis. , 2009, Pharmacological research.
[84] Y. Moriwaki,et al. Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro. , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[85] S. Sébillaud,et al. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis , 2008, Arthritis research & therapy.
[86] D. Puleo,et al. Immune System and Inflammation , 2003, Indian journal of pharmacology.
[87] J. Pelletier,et al. The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. , 2007, Arthritis and rheumatism.
[88] P. Komesaroff,et al. The anti-atherogenic effects of thiazolidinediones. , 2007, Current diabetes reviews.
[89] S. Edelson,et al. Effect of pioglitazone treatment on behavioral symptoms in autistic children , 2007, Journal of Neuroinflammation.
[90] J. Hardies,et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.
[91] A. Krentz,et al. Type 2 diabetes, psoriasis and thiazolidinediones , 2006, International journal of clinical practice.
[92] D. Hornung,et al. Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs , 2005 .
[93] J. Pelletier,et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. , 2005, Arthritis and rheumatism.
[94] T. Vogt,et al. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. , 2005, Rheumatology.
[95] G. Wells,et al. Celecoxib for rheumatoid arthritis. , 2017, The Cochrane database of systematic reviews.
[96] Susan M. Kilroy,et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. , 2002, The Journal of clinical investigation.
[97] T. Mayumi,et al. PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. , 2002, European journal of pharmacology.
[98] C. Day. Thiazolidinediones: a new class of antidiabetic drugs , 1999, Diabetic medicine : a journal of the British Diabetic Association.